Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

Ghassan K. Abou-Alfa, MD
Published: Wednesday, Nov 08, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.

Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.

  <<< View more from the 2017 Chemotherapy Foundation Symposium



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x